Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Currus Biologics, an Australia-based cancer immunotherapy developer spun out of Peter MacCallum Cancer Centre, has secured A$10m ($7.7m) in a funding round led by the Brandon Capital Partners-managed Medical Research Commercialisation Fund, with participation from multi-university venture fund Uniseed, according to the Australian Financial Review. Currus is the oncology research centre’s first investor-led spinout. It will use the money to advance its research aimed at solid tumours, including breast and pancreatic cancers, towards a product suitable for human clinical trials.
Koala Tech, a Japan-based semiconductor laser developer spun out of Kyushu University, has raised ¥400m ($3.6m) in a round led by Beyond Next Ventures (BNV) and backed by Sony Innovation Fund, a vehicle for electronics manufacturer Sony, chemicals vendor Tanaka Ai, QB Capital, TechAccel Ventures, FFG Venture Business Partners, Shinsei Corporate Investment and SMBC Venture Capital, the latter three being subsidiaries of financial services firms Fukuoka Financial Group, Shinsei…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
